Vericel (US:VCEL)2025-07-03 13:09Company Overview - Vericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets[6, 11, 18, 22, 99] - The company utilizes an innovative advanced therapy platform, combining devices and biologics that use a patient's own cells to repair tissue and restore function[10] Financial Performance & Market Opportunity - The company achieved 45% trailing twelve-month product revenue growth[12] - Total trailing twelve-month product revenues reached $90.9 million as of December 31, 2018[13] - Vericel is operating in addressable markets valued at over $2 billion[14] - The company has cash and short-term investments of approximately $83 million with no debt as of December 31, 2018[22, 98] MACI Product Highlights - Cartilage defects are found in approximately 60% of knee arthroscopies[33, 34] - MACI demonstrated statistically significantly greater improvement in KOOS pain and function scores compared to microfracture at year 2 (p = 0.001)[52, 53] - 87.50% of patients responded to MACI treatment compared to 68.10% with microfracture (p = 0.016)[55, 56] Epicel Product Highlights - Epicel is a permanent skin replacement for full-thickness burns covering 30% or more of the total body surface area[76] - Data demonstrates a lower mortality rate for Epicel patients compared to the National Burn Repository[82] - The addressable market for Epicel in the U S is estimated at $120 million[86]